Context Therapeutics (CNTX)
NASDAQ:CNTX
Want to see CNTX full AI Analyst Report?
CNTX Stock Chart & Stats
$2.43
$0.09(8.26%)
At close: 4:00 PM EST
$2.43
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $3.62
Previous CloseN/A
Volume293.07K
Average Volume (3M)830.13K
Market Cap
$218.67M
Enterprise Value$164.43M
Total Cash (Recent Filing)$54.53M
Total Debt (Recent Filing)$282.42K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume775,845
30 Day Avg. Volume830,128
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.09K
Enterprise Value/Ebitda-3.86
Forecast
1Y Price Target
$5.83Price Target Upside140.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Addressable Patient PopulationUpdated diagnostic data indicating a larger-than-previously-estimated CLDN6-high patient population could broaden the addressable market for the lead ovarian cancer program.
Clinical Pipeline ProgressAdvancement of multiple bispecific T-cell engager programs toward first-in-human trials and narrowed timelines for interim readouts provides several potential clinical data catalysts.
Regulatory SupportFast Track Designation for the CLDN6-targeted candidate in platinum-resistant ovarian cancer supports an expedited development pathway and may reduce regulatory risk for that program.
Bears Say
Dose Optimization UncertaintyThe maximum tolerated dose has not been established, creating uncertainty around the optimal therapeutic dose and dosing strategy for achieving durable benefit.
Financial Runway And Dilution RiskAvailable cash relative to current spending suggests limited runway and raises the prospect of additional financing that could dilute shareholders.
Safety And Tolerability ConcernsHigher-than-anticipated drug exposures prompted dose adjustments and a pause in a higher-dose cohort, highlighting ongoing safety and tolerability risks for lead programs.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $3.62 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $218.67M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 93 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.021.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went down -3.32%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (140.05% Upside)
$5.83 (140.05% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.25%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
-30.20%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.83
▲(140.05% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.87% Mutual Funds
0.11% Other Institutional Investors
88.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---